Coal Garden

Meiyuan Bioscience, frequently referred to as Coal Garden in translated literature, is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of mRNA-based therapeutics and vaccines. Founded in 2021 by a team of scientists with extensive experience in lipid nanoparticle (LNP) delivery systems, the company focuses on creating a robust platform for infectious disease prevention and oncology. Meiyuan's lead programs include a next-generation mRNA vaccine for COVID-19 and a pipeline of candidates targeting shingles and various solid tumors. The company leverages proprietary LNP technology to optimize the thermal stability and delivery efficiency of its RNA candidates, aiming to overcome common logistical barriers in mRNA medicine. Meiyuan has successfully secured significant venture capital backing from prominent investors such as Hillhouse Capital and Matrix Partners China to accelerate its clinical and pre-clinical development.